The specter of generic competition has consistently loomed around copyright’s iconic drug, Sildenafil, sparking questions about the future of connected medicinal ventures. While early times saw substantial gains, the patent expiration has opened the door for discounted substitutes, potentially diminishing profitability and presenting a genuine da